In a comprehensive interview to Karan Thapar for The WireProf. Gagandeep Kang, who works at The Wellcome Trust Research Laboratory at the Christian Medical College in Vellore, said the precedent set by the Ebola and Nipah vaccines, both of which were cleared without completing their Phase 3 trials and obtaining their efficacy data, does not apply to Covid-19. She said this is both because of the differences in the disease and its mortality as well as the fact that we have other licensed products to tackle Covid-19. “I would ask why would you want to give a vaccine without efficacy emergency use authorization in these circumstances?” she said.